People: Biogen Idec Inc (BIIB.O)

BIIB.O on Nasdaq

320.12USD
15 Sep 2014
Price Change (% chg)

$-3.27 (-1.01%)
Prev Close
$323.39
Open
$323.40
Day's High
$323.97
Day's Low
$315.71
Volume
1,064,013
Avg. Vol
1,119,661
52-wk High
$358.89
52-wk Low
$221.07

Search Stocks

Artavanis-Tsakonas, Spyros 

Brief Biography

Dr. Spyros Artavanis-Tsakonas, Ph.D., is Senior Vice President, Chief Scientific Officer of Biogen Idec Inc. Prior to his appointment in May 2013, Dr. Artavanis-Tsakonas served as our interim Chief Scientific Officer while on sabbatical from Harvard Medical School from March 2012 to May 2013. Dr. Artavanis-Tsakonas has been a Professor of Cell Biology at the Harvard Medical School since 1999. Prior to that, from 1999 through 2012, he was Professor, Coll├Ęge de France, serving as Chair of Biology and Genetics of Development, and from 1999 to 2007, he was also the K.J. Isselbacher- P. Schwartz Professor at the Massachusetts General Hospital Cancer Center and Director of Developmental Biology and Cancer at the Harvard Medical School. Dr. Artavanis-Tsakonas is the scientific co-founder of Exelixis Pharmaceuticals, Inc., a drug discovery and development company, Cellzome, a drug discovery and development company, and Anadys Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Artavanis-Tsakonas obtained his M.Sc. in Chemistry from the Federal Institute of Technology, Zurich and a Ph.D. in Molecular Biology from the University of Cambridge, England. His postdoctoral research was completed at Biozentrum, University of Basel and Stanford University.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stelios Papadopoulos

--

George Scangos

15,015,100

Paul Clancy

4,486,260

Kenneth Di Pietro

3,254,520

Susan Alexander

2,162,200

John Cox

3,671,600
As Of 30 Dec 2013
Search Stocks